Graphique du cours de l'action BDTX
BDTX Prix
Black Diamond Therapeutics Inc
$1.7
-8.6%
$-0.16
À la fermeture : Jun 25, 16:00:00 GMT-4
$1.74
2.35%
$0.04
Post-Marché: Jun 25, 18:49:40 GMT-4
Retour
Black Diamond Therapeutics Inc (BDTX) Prix
Statistiques clés
Clôture préc.
$1.86
Prix d'ouverture
$1.86
Plage de la journée
$1.69 - $1.89
Plage de 52 semaines
$1.74 - $4.94
Volume
1.9M
Volume moyen
1.0M
Rendement en dividend
--
BPA (TTM)
-0.76
Capitalisation boursière
$99.7M
Qu’est-ce que BDTX ?
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 21 full-time employees. The company went IPO on 2020-01-30. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The firm is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. The company is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Fonctionnalités
© 2026 Edgen fonctionné par
